Clinical significance of homologous recombination deficiency score testing in endometrial Cancer

Autor: Anil K. Sood, Robert L. Coleman, Selanere Mangala, Placede Tshiaba, Keith A. Baggerly, Wei Hu, Thomas P. Conrads, Kirsten Timms, Chris Neff, Ying Wang, Kari L. Ring, Shannon N. Westin, Karen H. Lu, K.M. Darcy, R.L. Dood, G.L. Maxwell, Russell Broaddus, Gabriel Lopez-Berestein, Shannon Gallagher, Jean H. Siedel
Rok vydání: 2021
Předmět:
Zdroj: Gynecol Oncol
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2020.12.010
Popis: BACKGROUND: Homologous recombination deficiency (HRD) score is related to chemotherapy response in some cancers, but its role in endometrial cancer in not known. We determined frequency and clinical significance of alterations in the HR pathway in endometrial cancer. METHODS: 253 endometrioid endometrial adenocarcinoma (EEA) samples from two independent cohorts (discovery and replication) were tested for HRD score using the Myriad HRD assay, microsatellite instability (MSI) and tumor mutation burden (TMB) using a next generation sequencing assay. HRD scores were also generated on endometrial cancer cell lines and in vivo response to olaparib was assessed. RESULTS: ROC curves were employed to determine optimal cutoffs of HRD in relation to survival impact in endometrial cancer and a cutoff of HRD ≥ 4 was suggested for DFS using discovery cohort. Patients from two independent cohorts with HRD score ≥ 4 trended toward worse survival as compared to those with HRD score
Databáze: OpenAIRE